Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).
A study led by researchers at The Institute of Cancer Research (London, UK) has uncovered numerous ways of targeting prostate cancer.
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
In a landmark genetics study, a multi-institutional group of researchers have uncovered three distinct evolutionary paths for kidney cancer, allowing them to determine whether a tumor will be aggressive.
In the first-of-its-kind study, researchers have unearthed the unique genetic fingerprints of every bowel tumor and bowel cancer cell.
Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed.
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
The NHS are piloting centers in ten areas with the aim of speeding up diagnosis and detecting cancer earlier.
Larotrectinib becomes the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.